COVID-19 and liver dysfunction: Epidemiology, association and potential mechanisms
- PMID: 34428501
- PMCID: PMC8380064
- DOI: 10.1016/j.clinre.2021.101793
COVID-19 and liver dysfunction: Epidemiology, association and potential mechanisms
Abstract
Currently, there have been more than one hundred million confirmed cases of coronavirus disease 2019 (COVID-19), with two million deaths worldwide. This has caused a huge medical burden. Severe COVID-19 patients can experience multi-organ damage, including cardiac injury, kidney injury, and liver injury. About 2.0%-4.9% of COVID-19 cases involve patients with preexisting liver diseases. Additionally, preexisting liver diseases were reported and associated with severity (odds ratio (OR) or risk ratio (RR) = 1.48-1.70) and mortality (OR or RR = 1.08-2.65) among COVID-19 patients. Furthermore, the prevalence of liver injury was 16%-29% in COVID-19 patients. Higher prevalence of liver injury may worsen prognosis in patients (severity: OR or RR = 1.9-2.6; mortality: OR or RR = 1.1-4.0). The mechanisms of this association between liver injury and severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection are complex, including direct cholangiocyte damage induced by SARS-COV-2, cytokine storm, and drug-induced liver injury. In particular, drug-induced liver injury may be the most important reason. This review discusses the epidemiology of COVID-19 and liver dysfunction as well as potential mechanisms underlying the association between COVID-19 and liver dysfunction or other preexisting liver diseases. However, the association between preexisting liver diseases and COVID-19 prognosis and potential mechanisms underlying these associations require further prospective studies.
Keywords: COVID-19; Liver dysfunction; Systematic review.
Copyright © 2021 Elsevier Masson SAS. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no conflict of interest.
Figures
Similar articles
-
The Impact of COVID-19 on Liver Injury.Am J Med Sci. 2022 Feb;363(2):94-103. doi: 10.1016/j.amjms.2021.11.001. Epub 2021 Nov 6. Am J Med Sci. 2022. PMID: 34752738 Free PMC article. Review.
-
SARS-CoV-2 induced liver injury: Incidence, risk factors, impact on COVID-19 severity and prognosis in different population groups.World J Gastroenterol. 2023 Apr 28;29(16):2397-2432. doi: 10.3748/wjg.v29.i16.2397. World J Gastroenterol. 2023. PMID: 37179584 Free PMC article. Review.
-
COVID-19-associated gastrointestinal and liver injury: clinical features and potential mechanisms.Signal Transduct Target Ther. 2020 Nov 2;5(1):256. doi: 10.1038/s41392-020-00373-7. Signal Transduct Target Ther. 2020. PMID: 33139693 Free PMC article. Review.
-
Liver injury in COVID-19: A minireview.World J Gastroenterol. 2022 Dec 21;28(47):6716-6731. doi: 10.3748/wjg.v28.i47.6716. World J Gastroenterol. 2022. PMID: 36620342 Free PMC article. Review.
-
COVID-19 and the liver: overview.Eur J Gastroenterol Hepatol. 2021 Mar 1;33(3):309-311. doi: 10.1097/MEG.0000000000001808. Eur J Gastroenterol Hepatol. 2021. PMID: 32558697 Free PMC article. Review.
Cited by
-
The İmpact of Elevated Liver Enzymes and İntrahepatic Cholestasis of Pregnancy on the Course of COVID-19 in Pregnant Women.SN Compr Clin Med. 2022;4(1):184. doi: 10.1007/s42399-022-01267-1. Epub 2022 Aug 11. SN Compr Clin Med. 2022. PMID: 35971435 Free PMC article.
-
Imaging features of COVID-19-associated secondary sclerosing cholangitis on magnetic resonance cholangiopancreatography: a retrospective analysis.Insights Imaging. 2022 Aug 8;13(1):128. doi: 10.1186/s13244-022-01266-9. Insights Imaging. 2022. PMID: 35939241 Free PMC article.
-
Significantly Reduced Retinol Binding Protein 4 (RBP4) Levels in Critically Ill COVID-19 Patients.Nutrients. 2022 May 10;14(10):2007. doi: 10.3390/nu14102007. Nutrients. 2022. PMID: 35631143 Free PMC article.
-
Insight into COVID-19 associated liver injury: Mechanisms, evaluation, and clinical implications.Hepatol Forum. 2024 Jul 2;5(3):139-149. doi: 10.14744/hf.2023.2023.0025. eCollection 2024. Hepatol Forum. 2024. PMID: 39006140 Free PMC article. Review.
-
Current Views About the Link between SARS-CoV-2 and the Liver: Friends or Foe?Endocr Metab Immune Disord Drug Targets. 2024;24(6):642-650. doi: 10.2174/0118715303251985231009050626. Endocr Metab Immune Disord Drug Targets. 2024. PMID: 37846575
References
-
- World Health Organization. WHO coronavirus disease (COVID-19) situation dashboard. 2020 [cited 6 March 2021]. Available from: https://www.who.int/
-
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5. [PMID: 31986264 DOI: https://doi.org/] - DOI - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous